These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10202550)

  • 1. [Teicoplanin. New treatment potentials for gram-positive infections in the hospital].
    Iakovlev SV
    Antibiot Khimioter; 1999; 44(2):3-7. PubMed ID: 10202550
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging glycopeptide resistance in gram-positive organisms.
    von Gottberg A; Ferraz V; Dusé AG
    S Afr Med J; 2000 Nov; 90(11):1108-9. PubMed ID: 11196027
    [No Abstract]   [Full Text] [Related]  

  • 3. In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients.
    Rolston KV; Dholakia N; Ho DH; LeBlanc B; Dvorak T; Streeter H
    J Antimicrob Chemother; 1996 Aug; 38(2):265-9. PubMed ID: 8877541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Glycopeptide resistant enterococci. Occurrence, distribution, resistance transmission, significance].
    Klare I; Witte W
    Wien Klin Wochenschr; 1997 May; 109(9):293-300. PubMed ID: 9265387
    [No Abstract]   [Full Text] [Related]  

  • 5. [Vancomycin and teicoplanin: differential aspects].
    Cobo J
    Enferm Infecc Microbiol Clin; 1995 Dec; 13(10):600-10. PubMed ID: 8808477
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy of resistant gram-positive infection: value of glycopeptide antibiotics vancomycin and teicoplanin].
    Waldvogel F
    Schweiz Med Wochenschr; 1993 Dec; 123(50):2353-6. PubMed ID: 8272810
    [No Abstract]   [Full Text] [Related]  

  • 7. What do I need to know about glycopeptide antibiotics?
    Li S; Starkey ES
    Arch Dis Child Educ Pract Ed; 2016 Dec; 101(6):323-326. PubMed ID: 27389546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients.
    Wilson AP; Cepeda JA; Hayman S; Whitehouse T; Singer M; Bellingan G
    J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycopeptide resistance in gram-positive pathogens.
    Fraimow HS; Shlaes DM
    Adv Exp Med Biol; 1995; 390():81-95. PubMed ID: 8718604
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT; Schønheyder H; Pers C; Thomsen VF
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.
    Arhin FF; Moeck G; Draghi DC; Pillar CM; Sahm DF
    Int J Antimicrob Agents; 2010 Nov; 36(5):474-6. PubMed ID: 20846829
    [No Abstract]   [Full Text] [Related]  

  • 12. Teicoplanin or vancomycin in the treatment of gram-positive infections?
    Murphy S; Pinney RJ
    J Clin Pharm Ther; 1995 Feb; 20(1):5-11. PubMed ID: 7775615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nosocomial methicillin-resistant staphylococci that remain sensitive to non-beta lactam antibiotics].
    Manfredi R; Nanetti A; Morelli S; Valentini R; Ferri M; Calza L; Chiodo F
    Recenti Prog Med; 2003; 94(7-8):344. PubMed ID: 12868245
    [No Abstract]   [Full Text] [Related]  

  • 14. Expression of glycopeptide-resistance gene in response to vancomycin and teicoplanin in the cardiac vegetations of rabbits infected with VanB-type Enterococcus faecalis.
    Lefort A; Arthur M; Depardieu F; Chau F; Pouzet C; Courvalin P; Fantin B
    J Infect Dis; 2004 Jan; 189(1):90-7. PubMed ID: 14702158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
    Roberts KD; Sulaiman RM; Rybak MJ
    Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zeckel ML. A closer look at vancomycin, teicoplanin and antimicrobial resistance. J Chemother 1997; 9: 311-335.
    Nathwani D
    J Chemother; 1998 Jun; 10(3):266-70. PubMed ID: 9669655
    [No Abstract]   [Full Text] [Related]  

  • 17. [The use of teicoplanin for Gram-positive infections in patients with kidney transplantation].
    Jákics J; Gálffy Z; Hernold L; Rácz A; Perner F
    Orv Hetil; 1996 Jun; 137(25):1355-8. PubMed ID: 8757082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teicoplanin in the treatment of serious infection.
    Schaison G; Graninger W; Bouza E
    J Chemother; 2000 Nov; 12 Suppl 5():26-33. PubMed ID: 11131961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of in vitro activity of teicoplanin against gram-positive anaerobic bacteria.
    Anzivino D; Nani E; Gulletta E; Lembo M; Covelli B
    J Chemother; 1989 Jul; 1(4 Suppl):201-2. PubMed ID: 16312368
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.